Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Carlos, CA, US. The stock last traded at $56.21, down 1.21% on the session, giving a market capitalisation of $8.12B. On trailing twelve-month figures it carries a trailing P/E of -7.36, a net margin of 0.0%. Its beta of 1.22 implies it has historically moved more than the broad market.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Vaxcyte, Inc. is most often compared with the following Healthcare names: